Resources

BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib

Leukemia & lymphoma, Vol. 62, Issue 6, Pages 1528-1531, 2021

PMID: 33478278

Mutations in the BCR-ABL1 kinase domain (BCR-ABL1 KD) is one of the most common determinants of tyrosine kinase inhibitor (TKI) resistance in patients with chronic myelogenous leukemia (CML) [1].

Read More

  https://www.ncbi.nlm.nih.gov/pubmed/33478278

 

Considering Genomic Research?

    Fields marked in * is mandatory to fill
     
     
     

    2024 © MedGenome • All Rights Reserved
    Request a Quote